

Catherine Handy Marshall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3666178/publications.pdf>

Version: 2024-02-01

26
papers

2,131
citations

687363
13
h-index

580821
25
g-index

27
all docs

27
docs citations

27
times ranked

5996
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Coronary artery calcium is associated with increased risk for lung and colorectal cancer in men and women: the Multi-Ethnic Study of Atherosclerosis (MESA). <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 708-716. | 1.2 | 7 |
| 2 | Clinical and genomic features of <i>SPOP</i> -mutant prostate cancer. <i>Prostate</i> , 2022, 82, 260-268. | 2.3 | 20 |
| 3 | Extreme Responses to a Combination of DNA-Damaging Therapy and Immunotherapy in CDK12-Altered Metastatic Castration-Resistant Prostate Cancer: A Potential Therapeutic Vulnerability. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 183-188. | 1.9 | 3 |
| 4 | Making National Cancer Institute's Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study. <i>JMIR Cancer</i> , 2022, 8, e33859. | 2.4 | 0 |
| 5 | A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. <i>European Urology</i> , 2021, 79, 692-699. | 1.9 | 49 |
| 6 | Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1623-1630. | 7.0 | 33 |
| 7 | Fitness and prostate cancer screening, incidence, and mortality: Results from the Henry Ford Exercise Testing (FIT) Project. <i>Cancer</i> , 2021, 127, 1864-1870. | 4.1 | 6 |
| 8 | Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2021, 128, 366-373. | 2.5 | 11 |
| 9 | Multidisciplinary prevention and management strategies for colorectal cancer and cardiovascular disease. <i>European Journal of Internal Medicine</i> , 2021, 87, 3-12. | 2.2 | 10 |
| 10 | Differential Activity of PARP Inhibitors in <i>BRCA1</i> - Versus <i>BRCA2</i> -Altered Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 1200-1220. | 3.0 | 17 |
| 11 | Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies. <i>Journal of Urology</i> , 2021, 206, 623-629. | 0.4 | 4 |
| 12 | Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline <i>ATM</i> versus <i>BRCA2</i> mutations. <i>Prostate</i> , 2021, 81, 1382-1389. | 2.3 | 10 |
| 13 | Healthy Lifestyle Benefits Both Cancer and Cardiovascular Disease. <i>JACC: CardioOncology</i> , 2021, 3, 675-677. | 4.0 | 6 |
| 14 | Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer. <i>European Urology</i> , 2020, 77, 14-21. | 1.9 | 51 |
| 15 | Association between coronary artery calcium and cardiovascular disease as a supporting cause in cancer: The CAC consortium. <i>American Journal of Preventive Cardiology</i> , 2020, 4, 100119. | 3.0 | 10 |
| 16 | Therapeutic targeting of the DNA damage response in prostate cancer. <i>Current Opinion in Oncology</i> , 2020, 32, 216-222. | 2.4 | 11 |
| 17 | Mounting Weight of Evidence on the Importance of Body Weight for Men With Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 2007-2009. | 1.6 | 2 |
| 18 | Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , 2020, 395, 1907-1918. | 13.7 | 1,395 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches. <i>Cancer Treatment and Research Communications</i> , 2020, 23, 100164. | 1.7 | 22 |
| 20 | Coronary Artery Calcium and the Age-Specific Competing Risk of Cardiovascular Versus Cancer Mortality: The Coronary Artery Calcium Consortium. <i>American Journal of Medicine</i> , 2020, 133, e575-e583. | 1.5 | 12 |
| 21 | Coronary Artery Calcium as a Synergistic Tool for the Age- and Sex-Specific Risk of Cardiovascular and Cancer Mortality: The Coronary Artery Calcium Consortium. <i>Journal of the American Heart Association</i> , 2020, 9, e015306. | 3.7 | 15 |
| 22 | Cardiorespiratory fitness and incident lung and colorectal cancer in men and women: Results from the Henry Ford Exercise Testing (FIT) cohort. <i>Cancer</i> , 2019, 125, 2594-2601. | 4.1 | 19 |
| 23 | Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. <i>European Urology</i> , 2019, 76, 452-458. | 1.9 | 109 |
| 24 | Unprocessed Red Meat and Processed Meat Consumption: Dietary Guideline Recommendations From the Nutritional Recommendations (NutriRECS) Consortium. <i>Annals of Internal Medicine</i> , 2019, 171, 756. | 3.9 | 227 |
| 25 | CDK12 inactivation across solid tumors: an actionable genetic subtype. <i>Oncoscience</i> , 2019, 6, 312-316. | 2.2 | 15 |
| 26 | Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 59-65. | 3.9 | 67 |